论文部分内容阅读
目的观察转移相关粘附分子拼接变异体CD44v6在人胃癌组织中的不同表达,探讨CD44v6与胃癌病理生物学行为之间的关系,评价CD44v6可否作为一个新的客观预测胃癌细胞转移潜能和胃癌患者预后的可靠生物学指标.方法采用鼠抗人CD44v6特异性mAb,对45例早期胃癌,22例中期胃癌和103例晚期胃癌手术切除标本之胃原发灶与转移灶进行了ABC免疫组化检测.应用χ2检验和Logrank检验方法对结果做统计学分析.结果CD44v6在晚期胃癌中的检出率为466%(48/103),明显高于早期胃癌(267%,12/45)和中期胃癌(273%,6/22,P<001).伴淋巴结转移和伴肝脏转移之胃癌CD44v6检出率分别为49%(50/102)和714%(5/7),明显高于不伴转移的胃癌(186%,11/59,P<001).肠型胃癌中CD44v6检出率为449%(48/107),明显高于弥漫型胃癌(274%,17/62,P<005).但是,CD44v6的表达与胃癌原发灶大小和组织学类型及分化程度未见明显相关.CD44v6阳性胃癌患者的术后生存期显著短于CD44v6阴性胃癌的患者(P=00002).结论?
Objective To observe the differential expression of CD44v6, a variant of adhesion-associated adhesion molecule, in human gastric cancer tissues, and to explore the relationship between CD44v6 and the pathological biological behavior of gastric cancer. To evaluate whether CD44v6 can objectively predict the metastatic potential of gastric cancer cells and the prognosis of gastric cancer patients. Reliable biological indicators. METHODS: ABC immunohistochemistry was performed on the gastric primary and metastatic lesions of 45 surgically resected specimens of 45 patients with early gastric cancer, 22 patients with intermediate gastric cancer and 103 patients with advanced gastric cancer using mouse anti-human CD44v6-specific mAb. The results were statistically analyzed using χ2 test and Logrank test. Results The detection rate of CD44v6 in advanced gastric cancer was 46.6% (48/103), which was significantly higher than that of early gastric cancer (26.7%, 12/45) and intermediate gastric cancer (27.5%, 6/22, P. <001). The detection rate of CD44v6 in gastric cancer with lymph node metastasis and liver metastasis was 49% (50/102) and 71.4% (5/7), respectively, which was significantly higher than that of gastric cancer without metastasis (18.6%, 11/59). , P<001). The detection rate of CD44v6 in intestinal type gastric cancer was 44.9% (48/107), which was significantly higher than that of diffuse type gastric cancer (27.4%, 17/62, P<0. 05). However, there was no significant correlation between CD44v6 expression and the size, histological type and differentiation of primary gastric cancer. The survival time of CD44v6 positive gastric cancer patients was significantly shorter than that of CD44v6 negative gastric cancer patients (P=00002). in conclusion?